BioCision is a leading supplier of cell cryopreservation products, systems, and solutions announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), for development of a cell thawing solution based on BioCision’s proprietary ThawSTAR technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.
The new ThawSTAR automated cell thawing system that will be developed as a result of this collaboration is an expansion of BioCision’s technology platform and will be made available commercially. BioCision is also developing other vial formats to address the needs of the larger cell therapy market. BioCision’s ThawSTAR system utilizes a patent pending adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial, thus providing a standardized thawing process, eliminating variability that could have a detrimental effect on the safety and efficacy of the cell therapy, and providing a significant reduction in cell handling risk in a clinical setting.
Conventional thawing methods, including swirling vials in warm water baths or rolling vials between hands can result in variable cell viabilities and can increase contamination concerns..
BioCision is a life science research and development company that develops products and solutions for process standardization throughout the healthcare industry through the application of advanced thermal regulation principles and technologies.
Subscribe to PharmaTutor News Alerts by Email >>
